Posts in IP News

The appellants are appealing from a series of inter partes review (IPR) proceedings at the Patent Trial and Appeal Board (PTAB) where the Board made the controversial decision to deny motions to dismiss the IPRs on a sovereign immunity defense raised by the St. Regis tribe. On appeal, St. Regis and Allergan asks the Federal Circuit to determine whether the PTAB erred either in holding that tribal immunity does not apply to IPR proceedings and in deciding that Allergan was the “effective patent owner,” enabling the IPRs to proceed in the St. Regis tribe’s absence even if tribal immunity applied.

This article examines Federal Circuit case law analyzing validity challenges to method of treatment patent claims where the claims at issue are alleged to recite an inherent property of a method or molecule taught in the prior art. While Federal Circuit case law challenging method of treatment claims on inherent anticipation grounds is generally globally consistent and reasonably straightforward, the court’s inherent obviousness case law is less so.

How do you create – how do you harness that value and how do you turn it into something that is meaningful for the people that own the intellectual property? We have sessions looking at specific industries, so we’re looking at things like semiconductors and the rise of artificial intelligence. We’re looking at how big data can be used to harness IP value. We’ve got two really interesting sessions that I’m looking forward to where we’re putting different scenarios to panels of chief IP officers and asking them how they would react to those scenarios.

Earlier today the USPTO announced proposed rulemaking that would change the prior policy of using the Broadest Reasonable Interpretation (BRI) standard for construing unexpired and proposed amended patent claims in PTAB proceedings under the America Invents Act and instead use the Phillips claim construction standard.. The new standard proposed by the USPTO is the same as the standard applied in Article III federal courts and International Trade Commission (ITC) proceedings, a change critics of the PTAB process have urged for many years in order to bring uniformity to post grant challenges across forums… The USPTO is also proposing to amend the rules for PTAB trials to add that the USPTO will consider any prior claim construction determination concerning a term of the claim in a civil action, or an ITC proceeding, that is timely made of record in an Inter Partes Review (IPR), Post Grant Review (PGR), or Covered Business Method (CBM) proceeding.

The patents discussed below are all landmark inventions and were conceived by inventors inducted into the National Inventors Hall of Fame (NIHF). Would these ground-breaking inventions, that helped set the course of humanity, be patentable today? … The point is that at first blush it’s not readily clear whether these patents would be found subject matter eligible, demonstrating that the uncertainty created by the Supreme Court with respect to patent subject matter eligibility has few bounds – even impacting the most celebrated inventions of our most honored inventors… If we cannot determine with reasonable certainty how all of these inventions would fare if judged under recent Supreme Court case law, then no one can truly teach Patent Subject Matter Eligibility 101.

More than half a century ago, the Supreme Court announced a “simple but fundamental rule” of administrative law: “that a reviewing court, in dealing with a determination or judgment which an administrative agency alone is authorized to make, must judge the propriety of such action solely by the grounds invoked by the agency.” Chenery II, 332 U.S. at 196 (emphasis added). Thus, an agency’s “action must be measured by what [the agency] did, not by what it might have done,” SEC v. Chenery Corp., 318 U.S. 80, 93–94 (1943) (Chenery I), so if the agency’s “grounds are inadequate or improper, the court is powerless to affirm the administrative action by substituting what it considers to be a more adequate or proper basis,” Chenery II, 332 U.S. at 196… Unfortunately, Chenery is yet another baseline legal norm that is not given due respect in the Federal Circuit. That court swims against the tide of Chenery’s expansion, enacting a restriction on its operation that dramatically reduces the rule’s scope.

The date of patent number 10,000,000 will be June 19, 2018. We feel this one is the easiest part of the prediction. We also think the USPTO will award Patent 10,000,000 to Application 13/666670 – SEARCH SPACE DESIGN FOR E-PDCCH IN WIRELESS COMMUNICATION NETWORKS from Qualcomm Inc.

What follows is a letter on the topic of PTAB reform that will be sent to USPTO Director Andrei Iancu on Monday, May 14, 2018. The letter seeks urgent action on the Patent Trial and Appeal Board in order to bring balance to a process that has tormented inventors for the last 6 years. We already have over 100 signatures from patent owners, patent attorneys, investors and inventors. If you would like to sign onto this letter please visit http://100patentowners.org.

For many years, foreign companies were reluctant to seek and enforce intellectual property protection in China.  A combination of challenging litigation with low damages, the lack of ability to effectively enforce judgments, allegations of protectionism by the courts; a lack of ability to patent certain subject matter, a lack of transparency on legal matters and other factors made China a less desirable jurisdiction.  The Chinese intellectual property legal system has matured rapidly, however.  From improvements in the scope of allowable patent subject matter to enhancements of litigation options, and a strong desire by China to be seen as having a level playing field for all parties, China deserves a second look… More companies are looking to China as a stand-alone enforcement jurisdiction, as a cost-effective second front to open in conjunction with US litigation.

On Wednesday, April 25th, the Court of Appeals for the Federal Circuit issued a precedential decision in Gilead Sciences v. Merck & Co. et. al., which affirmed a lower court’s ruling that Merck could not assert claims from two patents against Gilead because Merck had unclean hands regarding the patents. The case, coming out of the Northern District of California, involves patents covering methods for effectively treating the hepatitis C virus (HCV)… Reviewing the facts of the case, the Federal Circuit panel found sufficient evidence supporting the district court’s findings of serious business misconduct by Merck, that Merck’s misconduct was related to the litigation and that litigation misconduct had occurred based on false testimony provided by Merck’s non-firewalled patent lawyer, who had originally testified that he was not a party to the March 2004 phone call with Pharmasset.

In 01 Communique Lab v. Citrix Systems, the Federal Circuit rejected Communique’s appeal. The court properly relied on a comparison of the allegedly infringing GoToMyPC product to the asserted patent claims, as shown by careful jury instructions. Citrix’s comparison to the BuddyHelp prior art, in aid of a legitimate defense, did not cause prejudice to Communique. In reaching its decision, the Court noted that claim terms must be construed the same way for both invalidity and infringement. Thus, if a narrow construction was appropriate for validity in the reexamination to avoid the prior art, a broader construction should not be applied against alleged infringers.

On Thursday, April 20th, the Court of Appeals for the Federal Circuit issued a decision in Medinol Ltd. v. Cordis Corporation et. al. which vacated and remanded a lower court’s ruling that claims of patent infringement alleged by Israeli pharmaceutical firm Medinol were barred by the equitable defense of laches. The Federal Circuit’s decision comes after the U.S. Supreme Court overturned the Federal Circuit’s previous precedence on laches as an equitable defense in SCA Hygiene Products v. First Quality Baby Products, decided last year. The case was decided by a panel consisting of Circuit Judges Timothy Dyk, Jimmie Reyna and Kara Stoll.

Polsinelli announced the addition of prominent technology and intellectual property attorney William A. Tanenbaum to its New York office.  Tanenbaum joins the firm’s Technology Transactions & Data Privacy group and will serve as Co-Chair of the Healthcare Technology & Innovation Group.  His practice focuses on transactions, litigation, and strategic counseling in the intellectual property, technology, cybersecurity, health care IT and IP, financial services IT and IP, outsourcing and data-driven business sectors.       

In a move that recognizes the importance of innovation and IP rights – and the need for diverse audiences to understand how they work – the Canadian government has announced that it is investing $88.3M (CD) to create a new IP strategy that incorporates IP awareness and education.

FisherBroyles LLP, the nation’s first and world’s largest cloud-based distributed law firm partnership, announced today that John Eisenhart, Elizabeth Haanes, James W. Hill, Keats Quinalty and Cara Crowley-Weber have joined the firm as partners and members of the Patent Prosecution team, which is part of the firm’s Intellectual Property (IP) practice group.